Skip to main content

Day: October 16, 2020

Trius Announces Shareholder Meeting Results and Name Change to TRU Precious Metals Corp.

FREDERICTON, New Brunswick, Oct. 16, 2020 (GLOBE NEWSWIRE) — Trius Investments Inc. (“Trius” or the “Company”) (TSXV:TRU) is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held earlier today.Shareholders approved all routine and special items of business, including electing each of the directors nominated by management, namely Joel Freudman, Damian Lopez, Marisa Muchnik and Peter van Dijken.As the shareholders of the Company have approved a name change, among other things, the Board has determined to change the name of the Company to “TRU Precious Metals Corp.” Subject to TSXV approval, the new name is anticipated to take effect next week. Trius’ common shares will continue to trade on the TSXV under the symbol “TRU” following the name change.Trius President and CEO Joel Freudman...

Continue reading

Vornado Completes $500 Million Refinancing of PENN11

NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) — VORNADO REALTY TRUST (NYSE: VNO) announced today that it has completed a $500 million refinancing of PENN11, a 1.2 million square foot Manhattan office building. The interest-only loan carries a rate of LIBOR plus 2.75% (currently 2.90%) and matures in October 2025, as fully extended.The loan replaces the previous $450 million loan that bore interest at a fixed rate of 3.95% and was scheduled to mature in December 2020.Vornado Realty Trust is a fully-integrated equity real estate investment trust.CONTACT:JOSEPH MACNOW(212) 894-7000Certain statements contained herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may...

Continue reading

Ziopharm Oncology Announces Receipt of Shareholders’ Intent to Solicit Written Consents

BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it has received a notice, and acknowledges the filing of, a preliminary consent solicitation statement by WaterMill Asset Management Corp., Mr. Robert W. Postma and affiliated parties who together report to own 7,173,650 shares of Ziopharm, stating they intend to solicit the written consent of stockholders to remove without cause four members of the Company’s Board of Directors, amend several bylaws and elect the three individuals to the Company’s Board of Directors, including Mr. Postma himself. The Company has issued the following statement commenting on the notice:“Our Board and management are committed to act in the best interests of its stockholders to create sustainable long-term value. We understand...

Continue reading

WEYCO Group, Inc. Third Quarter 2020 Earnings Conference Call

Milwaukee, WI, Oct. 16, 2020 (GLOBE NEWSWIRE) — WEYCO Group, Inc. (NASDAQ: WEYS), a global marketer of footwear, plans to announce third quarter 2020 financial results after the close on Tuesday, November 3, 2020.  Additionally, Thomas W. Florsheim, Jr., Chairman and CEO, will host a conference call on Wednesday, November 4, 2020, at 11:00 a.m. Eastern Time to discuss the financial results in more detail. To participate in the call, you will first need to pre-register online. Pre-registration takes only a few minutes and you may pre-register at any time, including up to and after the call start time. To pre-register, please go to: http://www.directeventreg.com/registration/event/8083903.  The pre-registration process will provide the conference call phone number and a passcode required to enter the call. A replay will be available...

Continue reading

Playa Hotels & Resorts Named One of the 2020 Best Small & Medium Workplaces™ by Great Place to Work® and Fortune

FORT LAUDERDALE, Fla., Oct. 16, 2020 (GLOBE NEWSWIRE) — Great Place to Work® and Fortune have honored Playa Hotels & Resorts N.V. (NASDAQ: PLYA, “Playa”), a leading owner and operator of all-inclusive resorts across Mexico and throughout the Caribbean, as one of the 2020 Best Small & Medium Workplaces™. The ranking is based on confidential survey feedback representing more than 189,000 employees working at small- and medium-sized businesses in the United States.Great Place to Work, a global people analytics and company culture research firm, evaluated more than 60 elements of team members’ experience on the job. These included the extent to which employees trust leaders, the respect with which people are treated, the fairness of workplace decisions, and how much camaraderie there is among the team.Rankings are based on...

Continue reading

Almadex Closes Private Placement

VANCOUVER, British Columbia, Oct. 16, 2020 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. (“Almadex” or the “Company”) (TSX-V: “DEX”) is pleased to announce that it has closed its previously announced non-brokered private placement with the issuance of 5,400,000 units (“Units”) at $0.25 per Unit (the “Offering”).Each Unit consisted of one common share of the Company and one non-transferable common share purchase warrant (a “Warrant”). Each Warrant allows the holder to purchase one common share of the Company at a price of $0.40 per share until October 16, 2022.The Offering was made by way of a private placement to qualified investors in Canada, the United States of America and certain other jurisdictions where the Offering could lawfully be made. All securities issued and issuable under the Offering are subject...

Continue reading

Eton Pharmaceuticals Announces Closing of Public Offering

DEER PARK, Ill., Oct. 16, 2020 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,220,000 shares of common stock at a public offering price of $7.00 per share. The total offering included 420,000 shares sold as a result of the underwriter’s exercise of its overallotment option in full.Gross proceeds to Eton Pharmaceuticals from this offering are approximately $22.5 million before deducting underwriting discounts, commissions and other offering expenses. Eton Pharmaceuticals intends to use the net proceeds from the offering primarily for general corporate purposes, which may include research and development activities, capital...

Continue reading

Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

VANCOUVER, British Columbia, Oct. 16, 2020 (GLOBE NEWSWIRE) — MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.Among the factors considered by the Company in pursuing the dual listing, Mydecine™ noted that the LSE currently has a limited number of sizable psychedelics-focused biotech companies. Mydecine, as a contributing member to Drug Science UK, the only completely independent, science-led drugs charity, believes the LSE listing will provide UK and European investors with greater, more local...

Continue reading

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO®in Newly Diagnosed AML Patients –CAMBRIDGE, Mass., Oct. 16, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the withdrawal of its European Marketing Authorization Application (MAA) for TIBSOVO® (ivosidenib tablets) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation. The decision is based on feedback from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) that the available clinical data from the company’ssingle arm, uncontrolled Phase 1 study do not sufficiently support a positive benefit-risk balance for the...

Continue reading

ATEC Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock

CARLSBAD, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, today announced the closing of its previously announced underwritten public offering of 13,142,855 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,714,285 additional shares of common stock, at a public offering price of $8.75 per share, for total gross proceeds of approximately $115.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ATEC.Morgan Stanley and Cowen acted as joint book-running managers in the offering. Canaccord Genuity acted as lead manager in the offering, with Lake Street Capital Markets and Northland...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.